Heritage

Successfully listed on NSE and BSE

Launch of International quality API- Products

Launched India’s First fully integrated facility for Dydrogesterone at Udaipur

Incorporated our Subsidiary, Incisive Health Care Pharma FZ-LLC in Dubai

Entered the specialty therapeutic respiratory pharmaceuticals segment with launch of ‘Mlife’ tablets

Neuro/Central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets

Incorporated our Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal

Entered the specialty therapeutic cardiovascular drugs segment with launch of ‘Cilaheart’ tablets and ‘Epifast’ tablets

Entered the specialty therapeutic diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets

Entered the female infertility segment with the launch of ‘Dydroboon Tablets’

Set up our manufacturing facility at Sikkim

Incorporated our Subsidiary, Lifestar Pharma LLC in the US

Incorporated our Subsidiary, Incisive Health Care Pharma Pte. Limited in Singapore

Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan

Set up our manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh

Setup our first R&D centre at IMT Manesar, Haryana

Launched ‘Preganews’ brand in the consumer healthcare segment

Set up our manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh

Entered the consumer healthcare segment with the launch of ‘Manforce’ brand

Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’

Raised ₹ 720 million from Monet Limited

Set up our first manufacturing facility at Paonta Sahib, Himachal Pradesh

Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’

Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’ tablets